Its sufficient levels in the body help improve blood pressure and heart rate, and promote metabolic health
10.1038/s41576-019-0158-7 55 LangQ.ZhangH.LiJ.YinH.ZhangY.TangW.et al (2008)
Disclosures: Kamalpreet Hara: Nothing to Disclose, Alberto Calleri: Nothing to Disclose, Tiffany Wu: Nothing to Disclose, Vijay Shah: Boehringer Ingelheim: Consultant, GSK: Consultant, GENFIT SA: Consultant, Intercept Pharmaceuticals, Inc.: Advisor, Korro Bio, Inc.: Consultant, Mallinckrodt Pharmaceuticals: Advisor, Novo Nordisk A/S: Consultant, Resolution Therapeutics, Ltd.: Advisor, Seal Rock Therapeutics, Ltd.: Consultant, Surrozen: Advisor, Patrick Kamath: Sequana: Advisor, NovoNordisk: Advisor, Douglas Simonetto: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose 1590 A PROSPECTIVE STUDY EVALUATING THE PREVALENCE OF STEATOTIC LIVER DISEASE AND ADVANCED FIBROSIS AND CIRRHOSIS IN OVERWEIGHT AND OBESE INDIVIDUALS IN THE UNITED STATES Alexander Yang 1 Monica Tincopa 1 Federica Tavaglione 2 Veeral Ajmera 1 Lisa Richards 1 Maral Amangurbanova 1 Christian Butcher 1 Christie Hernandez 1 Egbert Madamba 1 Seema Singh 1 Ricki Bettencourt 1 Bernd Schnabl 1 Claude Sirlin 1 Rohit Loomba 1 , 1 University of California, San Diego, 2 University Campus Bio-Medico of Rome Background: In 2023, new steatotic liver disease (SLD) nomenclature was introduced to include metabolic dysfunction-associated liver disease (MASLD), alcohol-associated liver disease (ALD), and the entity metabolic dysfunction and alcohol-associated liver disease (MetALD) accounting for those with both metabolic risk factors and significant alcohol use
doi: 10.1038/370555a0 82 McElvaneyNGBurdonJHolmesMGlanvilleAWarkPAThompsonPJet al
